Answers are grounded in this paper and cite their sources.
Clinical trials have proven the efficacy and safety of atezolizumab combined with bevacizumab (A+B) in treating unresectable hepatocellular carcinoma (uHCC). This study aimed to assess the cost-utility of A+B compared to best supportive care (BSC) among uHCC patients in Thailand.
No takes yet. Share an insight, caveat, or question.
Sriphoosanaphan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: